# Concurrent chemoradiotherapy with low dose weekly gemcitabine in stage III non-small cell lung cancer

## TL;DR

This study tests a low-dose gemcitabine chemoradiotherapy regimen for stage III non-small cell lung cancer, showing acceptable tolerability and survival rates.

## Contribution

Demonstrates the feasibility and efficacy of low-dose weekly gemcitabine as a radiosensitizer in concurrent chemoradiotherapy for stage III NSCLC.

## Key findings

- Median overall survival was 14 months with 55% and 38% one- and two-year survival rates.
- Radiation pneumonitis occurred in 31.8% of patients, but gemcitabine was well tolerated in most cases.
- Partial response was observed in 81.8% of patients evaluated for overall response.

## Abstract

Combined chemoradiotherapy (CRT) is the treatment of choice for stage III NSCLC. Gemcitabine (G) is a novel deoxycitidine analogue that has been proven to be a potent radiosensitizer. Twenty-two consecutive patients were treated with concurrent CRT to demonstrate the tolerability and efficacy of low dose G given weekly as radiosensitizer in stage III NSCLC.

Patients with KPS ≥70, adequate bone marrow reserve, with no prior radiotherapy (RT) and surgery were included. Eighteen patients had received prior induction chemotherapy (CT). G (75 mg/m2/week) was infused over 1 hour for 6 weeks. Thoracic RT was given two hours later over 6 weeks at 1.8 Gy/day fractions (total dose of 61.2 Gy). Pulmonary toxicity was evaluated with computed tomography scans in 6 weeks.

Median age was 60 years (range, 48–75), median follow-up was 15 months (range, 2–40). Sixty-eight percent of patients were male and median KPS score was 90. Conformal 3D-RT planning was used in 64% of patients. G was given for a median of 5 weeks (range 1–9). Twelve patients (54.6%) received all planned CT. G was stopped because of intolerance in 6 and death in 2 patients. Seven patients (31.8%) had radiation pneumonitis. Twenty patients were evaluated for overall response, 1 patient (4.5%) had clinical CR, 81.8% had PR while 9.5% had SD. Median overall survival (OS) was 14 ± 5 months (95% CI 3–25). One- and 2-year OS rates were 55% and 38%. Sixteen patients died of disease-related events (6 with progression of primary tumor, 8 due to metastatic disease), 2 patients died of other causes. One- and 2-year progression-free survival and local control rates were 56%, 27% and 79%, 51%, respectively.

G might be used as radiosensitizer for patients with stage III NSCLC who could not receive full doses CT with concurrent RT.